These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8147235)

  • 21. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
    de Andrade RP
    Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women.
    Oosterbaan HP
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():3-8. PubMed ID: 14677619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
    Renier M; Buytaert P
    Contraception; 1991 May; 43(5):413-21. PubMed ID: 1914456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH; Schindler AE; Endrikat J; Düsterberg B
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
    van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group.
    Contraception; 1994 Sep; 50(3):201-14. PubMed ID: 7805371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
    Andolsek KM
    Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30.
    Loudon NB; Kirkman RJ; Dewsbury JA
    Eur J Obstet Gynecol Reprod Biol; 1990 Mar; 34(3):257-66. PubMed ID: 2178992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
    Hampton RM; Fisher AC; Pagano S; LaGuardia KD
    Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():9-15. PubMed ID: 14677620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.
    Chavez A; DelConte A
    Eur J Contracept Reprod Health Care; 1999 Jun; 4(2):75-83. PubMed ID: 10427482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].
    Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K; Cibula D
    Ceska Gynekol; 1999 Jul; 64(4):246-54. PubMed ID: 10568064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study.
    Winkler UH; Oberhoff C; Bier U; Schindler AE; Gillain D
    Int J Fertil Menopausal Stud; 1995; 40(5):260-8. PubMed ID: 8556031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.